A Randomized, Placebo-Controlled, 4-Period, Crossover Study to Assess the Impact of MK-0431 (Sitagliptin) on Incretin Effect and the Role of Specific Incretin Hormones in Patients With Type 2 Diabetes Mellitus.

Trial Profile

A Randomized, Placebo-Controlled, 4-Period, Crossover Study to Assess the Impact of MK-0431 (Sitagliptin) on Incretin Effect and the Role of Specific Incretin Hormones in Patients With Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2014

At a glance

  • Drugs Sitagliptin (Primary) ; Exendin 9
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
    • 08 Oct 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top